

Daniel R Van Langenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8934605/publications.pdf>

Version: 2024-02-01

70
papers

1,752
citations

304701

22
h-index

289230

40
g-index

71
all docs

71
docs citations

71
times ranked

2445
citing authors

#	ARTICLE	IF	CITATIONS
1	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1037-1053.	3.7	225
2	Systematic review: fatigue in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 131-143.	3.7	171
3	A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 302-310.	1.3	99
4	Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2014, 27, 263-275.	2.5	96
5	Impact of Ethnicity, Geography, and Disease on the Microbiota in Health and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2906-2918.	1.9	79
6	Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 916-923.	2.8	72
7	Delving into disability in Crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 626-634.	1.3	59
8	Factors Associated with Physical and Cognitive Fatigue in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 115-125.	1.9	57
9	Chronic Pain in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1210-1217.	1.9	56
10	Sleep and physical activity measured by accelerometry in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 991-1004.	3.7	52
11	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. <i>World Journal of Gastroenterology</i> , 2017, 23, 6385-6402.	3.3	51
12	Objectively measured muscle fatigue in Crohn's disease: Correlation with self-reported fatigue and associated factors for clinical application. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 137-146.	1.3	50
13	Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2966-2976.	1.9	46
14	Cognitive impairment in Crohn's disease is associated with systemic inflammation, symptom burden and sleep disturbance. <i>United European Gastroenterology Journal</i> , 2017, 5, 579-587.	3.8	45
15	Unpromoted issues in inflammatory bowel disease: opportunities to optimize care. <i>Internal Medicine Journal</i> , 2010, 40, 173-182.	0.8	44
16	Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1135-1145.	3.7	40
17	Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 289-297.	1.3	39
18	Predicting response after infliximab salvage in acute severe ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1347-1352.	2.8	37

#	ARTICLE	IF	CITATIONS
19	Adverse clinical phenotype in inflammatory bowel disease: A cross sectional study identifying factors potentially amenable to change. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1250-1258.	2.8	33
20	The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: A single metropolitan Australian center experience. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 413-421.	1.3	32
21	Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: A small step for clinicians, a potentially large step for improving quality of care. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e367-e374.	1.3	27
22	Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: â€A cocktail best avoided, not stirredâ€™. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 469-472.	1.3	23
23	Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 682-688.	0.9	23
24	Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. <i>Intestinal Research</i> , 2022, 20, 101-113.	2.6	21
25	Inflammatory bowel disease serology in Asia and the West. <i>World Journal of Gastroenterology</i> , 2013, 19, 6207.	3.3	21
26	A dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre. <i>Frontline Gastroenterology</i> , 2012, 3, 137-142.	1.8	20
27	Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 280-288.	1.3	20
28	Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1174-1184.	3.7	20
29	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1462-1473.	1.9	15
30	Characterization of ulcerative colitisâ€™ associated constipation syndrome (proximal constipation). <i>JGH Open</i> , 2018, 2, 217-222.	1.6	12
31	Satisfaction with patient-doctor relationships in inflammatory bowel diseases: Examining patient-initiated change of specialist. <i>World Journal of Gastroenterology</i> , 2012, 18, 2212.	3.3	12
32	A virtual clinic increases antiâ€™TNF dose intensification success via a treatâ€™toâ€™target approach compared with standard outpatient care in Crohnâ€™s disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1342-1352.	3.7	11
33	Poor predictive value of breath hydrogen response for probiotic effects in IBS. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1731-1739.	2.8	10
34	Inflammatory Bowel Disease Clinical. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 121-154.	2.8	10
35	Faecal calprotectin delivers on convenience, cost reduction and clinical decisionâ€™making in inflammatory bowel disease: a realâ€™world cohort study. <i>Internal Medicine Journal</i> , 2019, 49, 94-100.	0.8	10
36	Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing. <i>Internal Medicine Journal</i> , 2015, 45, 1161-1166.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 226-231.	2.8	8
38	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1622-1631.	2.3	8
39	The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. <i>Internal Medicine Journal</i> , 2010, 40, 819-827.	0.8	7
40	The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 369-379.	1.9	7
41	The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease. <i>Intestinal Research</i> , 2021, 19, 158-170.	2.6	7
42	Gastrointestinal: Acute haemorrhage from a Dieulafoy lesion within a gastric diverticulum managed endoscopically. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1891-1891.	2.8	6
43	A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231982559.	2.5	6
44	Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110709.	3.2	6
45	Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based audit. <i>Internal Medicine Journal</i> , 2012, 42, e84-8.	0.8	5
46	Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 583-593.	1.3	5
47	Inflammatory Bowel Disease, Clinical. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, A311-A321.	2.8	4
48	Letter: ustekinumab dose intensification for loss of response "should we re-induce before shortening the dose interval?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 564-565.	3.7	4
49	Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1420-1425.	3.0	3
50	Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e69-e69.	1.9	3
51	Inflammatory bowel disease and superior mesenteric artery thromboembolism. <i>Intestinal Research</i> , 2020, 18, 130-133.	2.6	3
52	Maintaining Muscle Strength in Crohn's Disease: Can a Vitamin D Daily Keep Muscle Loss Away?. <i>Digestive Diseases and Sciences</i> , 2013, 58, 293-295.	2.3	2
53	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics. , 2019, , 243-255.		2
54	Inflammatory Bowel Disease Helpline Reduces Subsequent Inpatient Admission Rates. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 281-281.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 561-562.	3.7	2
56	Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 879-880.	3.7	2
57	Aminosalicylate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy. <i>GastroHep</i> , 2020, 2, 57-63.	0.6	2
58	Are All Symptoms in Patients in IBD Due to Occult Inflammation?. <i>American Journal of Gastroenterology</i> , 2010, 105, 2703.	0.4	1
59	P534 Co-prescription of allopurinol can overcome adverse events of thiopurine therapy and lead to remission in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S290-S291.	1.3	1
60	P378 Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S223.	1.3	1
61	Sa1951 Inpatient Variability in Adalimumab Drug Levels Within and Across Cycles in Crohn's disease. <i>Gastroenterology</i> , 2016, 150, S414.	1.3	1
62	Letter: overcoming secondary loss of response to infliximab "it is not the drug, it is how you use it!. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1028-1029.	3.7	1
63	Medical Management of Infliximab Failure in Acute Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1029-1029.	1.3	1
64	Faecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection: an Australian experience " effective, safe, yet room for improvement. <i>Internal Medicine Journal</i> , 2021, 51, 106-110.	0.8	1
65	Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 718-719.	3.7	1
66	Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 108-109.	3.7	1
67	Letter: rationalising aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1619-1620.	3.7	1
68	Capsule Endoscopy: Controversies of Patient Selection, Preparation and Outcomes. The Royal Adelaide Hospital Experience. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB322.	1.0	0
69	New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 10-11.	2.8	0
70	Editorial: methotrexate vs azathioprine " do differential rates of discontinuation settle the debate? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1529-1530.	3.7	0